IRIS
BOVIS, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.160
Totale 12.160
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 12.160
Totale 12.160
Salva come PNG Salva come JPEG
Città #
Genova 7.940
Vado Ligure 1.472
Rapallo 1.376
Genoa 1.332
Bordighera 40
Totale 12.160
Salva come PNG Salva come JPEG
Nome #
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 153
The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 153
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 151
The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 146
Bloodstream infections in patients living with HIV in the modern cART era 143
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 134
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 133
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 130
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 129
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 129
The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 124
The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 124
The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 124
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 123
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 122
The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis 121
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 121
The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 119
Delineating the application of ultrasound in detecting synovial abnormalities of subtalar joint in juvenile idiopathic arthritis 119
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients 118
The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 117
The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 117
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 117
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 116
Vascular factors predict polyneuropathy in a non-diabetic elderly population 116
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries 116
The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 115
The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 115
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 114
The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 113
The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 112
Non-invasive mitochondrial DNA quantification on day 3 predicts blastocyst development: a prospective, blinded, multi-centric study 112
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials 112
The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 111
The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 111
The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 111
The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 111
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. 110
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 110
Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy 110
Outpatient erbium:YAG (2940 nm) laser treatment for snoring: a prospective study on 40 patients 109
The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 109
The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 109
The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 109
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 108
Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. 107
Defining criteria for disease activity States in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. 107
The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 107
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 107
The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 107
The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 106
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 106
Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS 105
The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 105
Impact of acute-phase complications and interventions on 6-month survival after stroke. A prospective observational study 104
The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 104
The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 104
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 104
Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study 103
The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 103
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders 103
The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 102
The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 102
The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 102
The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 101
The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 100
The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 100
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 98
The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 98
The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 98
Classification criteria for autoinflammatory recurrent fevers 98
Three-Dimensional Shape and Surface Features Distinguish Multiple Sclerosis Lesions from Nonspecific White Matter Disease 97
Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data 96
Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas 96
A long-term prognostic value of CT angiography and exercise ECG in patients with suspected CAD 95
Coronary in-stent restenosis: Assessment with CT coronary angiography 93
The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 93
The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 92
The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 92
Haploientical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography 91
The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 90
The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 89
The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 88
Revised upper limb module for spinal muscular atrophy: 12 month changes 88
Stroke unit care in clinical practice: An observational study in the Florence center of the European Registers of Stroke (EROS) Project 84
A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis 82
Role of Alveolar β2-Adrenergic Receptors on Lung Fluid Clearance and Exercise Ventilation in Healthy Humans 82
Feasibility and diagnostic accuracy of a low radiation exposure protocol for prospective ECG-triggering coronary MDCT angiography 81
Management of acute ischemic stroke, thrombolysis rate, and predictors of clinical outcome 79
The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 79
The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 78
Bloodstream infections in patients living with HIV infection in the recent cART era: did something change?”. 76
Aortic annulus area assessment by multidetector computed tomography for predicting paravalvular regurgitation in patients undergoing balloon-expandable transcatheter aortic valve implantation: A comparison with transthoracic and transesophageal echocardiography 73
Next generation sequencing panel in undifferentiated autoinflammatory diseases identify patients with colchicine-responder recurrent fevers 70
Temporomandibular Joint Involvement is Associated with Quality of Life, Disability and High Disease Activity in Juvenile Idiopathic Arthritis 68
Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling 66
Methods of implementation of evidence-based stroke care in Europe European implementation score collaboration 62
Totale 10.653
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.455
article - articoli 47.046
book - libri 0
conference - conferenze 293
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 116
Totale 94.910
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.702 0 0 0 0 0 0 672 592 499 506 317 116
2020/20211.480 85 149 153 133 91 81 70 159 78 207 78 196
2021/20221.493 95 44 83 121 38 148 54 309 148 173 62 218
2022/20231.661 148 157 24 157 222 269 20 132 297 49 154 32
2023/20241.019 41 122 37 117 73 142 92 57 70 63 81 124
2024/20251.624 98 247 127 229 494 428 1 0 0 0 0 0
Totale 12.757